ClinicalTrials.gg
RecruitingNCT04731610RADIO-RYTHMICUpdated Apr 20, 2026

Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)

An interventional study of Radiotherapy and Surveillance after resection in Thymoma Malignant Recurrent, sponsored by Institut Curie. Recruiting at 21 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Institut Curie · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective of the study : to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.

02

Conditions studied

  • Thymoma Malignant Recurrent

Browse trials for

03

In context

Thymoma

133 studies on the registry are indexed under Thymoma; 37 are open to participants now.

This study's planned enrollment of 314 is above the median of 44 across 108 interventional studies indexed under Thymoma.

Browse Thymoma studies →

Lead sponsor

Institut Curie is the lead sponsor of 135 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 \< Age \< 75 years old
  2. performance status ≤1
  3. Preoperative chemotherapy is allowed. Maximum of 4 cycles are authorized. Surgery should be realized ≤ 2 months after the last chemotherapy injection.
  4. diagnosed thymoma at pathological examination of surgical specimen after pathological review; for note, centralized, real-time, systematic pathological review is standard through the RYTHMIC network in France
  5. Complete resection at pathological examination of the surgical specimen after surgery conducted through standard, recommended approach ensuring accurate assessment of resection status
  6. Stage IIb or III disease according to the Masaoka-Koga staging system; this corresponds to stage pT1a with capsule invasion, until stage pT3 N0 M0 in the 8th TNM staging system TNM UICC/AJCC
  7. Availability of thoracic Computed-Tomography (CT) scan with IV contrast (in the absence of ) or PET scan performed before surgery
  8. Availability of a thoracic Computed-Tomography (CT) scan with IV contrast (in the absence of contra-indications) showing absence of residual disease after surgical resection of the tumor
  9. Pulmonary function tests after surgery with ≥ 1L or ≥ 35% of the theoretical value and DLCO ≥ 40%
  10. Signature of form

Exclusion criteria

Exclusion Criteria:

- 1. Age > 75 years old 2. Histology of thymic carcinoma 3. Delivery of post-operative chemotherapy, concurrent chemotherapy to radiotherapy 4. Presence of microscopic or macroscopic residual tumor after surgery or (R1 or R2 resection) 5. Uncontrolled, pleural or pericardial effusion 6. Patients with prior radiation therapy to the thorax. Patients treated with conformal radiotherapy for prior breast or head and neck neoplasms should be discussed with PI 7. Evidence of severe or uncontrolled systemic disease as judged by the investigator 8. Recent (\< 6 months) severe cardiac disease (uncontrolled arrhythmia, congestive heart failure, infarction, pace-maker) or pulmonary disease. Controlled and non clinically symptomatic arrhythmia is allowed.

9. Current or past history of neoplasm diagnosed within the last 3 years, except: basal cell carcinoma of the skin, in situ carcinoma of the cervix, and bladder in situ. A patient diagnosed for another neoplasm 3 years ago or more, treated and considered as cured may be included in the study if all the other criteria are respected 10. Pregnancy or breast feeding or inadequate measures for women of during PORT 11. Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls, 12. Patients deprived of freedom or under guardianship

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
314 participants (estimated)

Study arms

  • Other
    Post-operative radiotherapy

    Tumour resection followed by radiotherapy.

    Other: Radiotherapy

  • Other
    Surveillance after tumour resection

    Tumour resection

    Other: Surveillance after resection

Interventions

  • OtherRadiotherapy

    postoperative radiotherapy after complete resection of thymoma

  • OtherSurveillance after resection

    Surveillance after tumour resection

06

What researchers measure

Primary outcomes

  1. Recurrence-Free survival (RFS)

    to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.

    Time frame: 3 years

Secondary outcomes

  1. Local-regional (pleural or pericardial) recurrence

    Local-regional (pleural or pericardial) recurrence; location of recurrence /removed

    Time frame: 3 years

07

Study locations

14 of 21 sites recruiting
  • CHU Caen
    Caen, 14000, France
    Recruiting
    • Simon DESHAYES, MD · Contact
    • Simon DESHAYES, MD · Principal investigator
  • CLCC François BACLESSE
    Caen, 14000, France
    Recruiting
    • Delphine LEROUGE, MD · Contact
    • Delphine LEROUGE, MD · Principal investigator
  • CLCC Georges François Leclerc
    Dijon, 21079, France
    Recruiting
    • Etienne MARTIN, MD · Contact
    • Etienne MARTIN, MD · Principal investigator
  • Centre Oscar Lambret
    Lille, 59000, France
    Recruiting
    • Florence LE TINIER, MD · Contact
    • Florence LE TINIER, MD · Principal investigator
  • CHU Lyon
    Lyon, 69002, France
    Recruiting
    • Thomas PIERRET, MD · Contact
    • Thomas PIERRET, MD · Principal investigator
  • AP-HM Hôpital Nord
    Marseille, 13005, France
    Recruiting
    • Pascal THOMAS, Pr · Contact
    • Pascal THOMAS, Pr · Principal investigator
  • Institut du Cancer de Montpellier
    Montpellier, 34090, France
    Not yet recruiting
    • Xavier QUANTIN, Pr · Contact
    • Xavier QUANTIN, Pr · Principal investigator
  • Antoine LACASSAGNE
    Nice, 06189, France
    Not yet recruiting
    • Jérôme DOYEN, MD · Contact
    • Jérôme DOYEN, MD · Principal investigator
  • Institut Curie
    Paris, 75005, France
    Recruiting
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
    Not yet recruiting
    • Aurélia ALATI, MD · Contact
    • Aurélia ALATI, MD · Principal investigator
  • Hôpital Bichat AP-HP
    Paris, 75018, France
    Recruiting
    • Valérie GOUNANT, Pr · Contact
    • Valérie GOUNANT, Pr · Principal investigator
  • CHU Haut Lévêque
    Pessac, 33604 Cedex, France
    Not yet recruiting
    • POUYPOUDAT, MD · Contact
    • Claudia POUYPOUDAT, MD · Principal investigator
  • CHU Rennes Hôpital Sud
    Rennes, 35056, France
    Recruiting
    • Charles RICORDEL, MD · Contact
    • Charles RICORDEL, MD · Principal investigator
  • CHU Rouen
    Rouen, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • CLCC Henri Becquerel
    Rouen, France
    Not yet recruiting
    • Sébastien THUREAU, MD · Contact
    • Sébastien THUREAU, MD · Principal investigator
  • Institut de Cancérologie de l'Ouest
    Saint-Herblain, 44805, France
    Recruiting
    • François THILLAYS, MD · Contact
    • François THILLAYS, Pr · Principal investigator
  • CHU Strasbourg
    Strasbourg, 67098, France
    Not yet recruiting
    • Pierre-Emmanuel FALCOZ, Pr · Contact
    • Pierre-Emmanuel FALCOZ, Pr · Principal investigator
  • Institut Claudius Regaud
    Toulouse, 31300, France
    Recruiting
    • Jonathan KHALIFA, MD · Contact
    • Jonathan KHALIFA, MD · Principal investigator
  • CHRU Tours
    Tours, 37044, France
    Recruiting
    • Eric PICHON, MD · Contact
    • Eric PICHON, MD · Principal investigator
  • Institut de Cancérologie de Lorraine Nancy
    Vandœuvre-lès-Nancy, 54519, France
    Recruiting
    • Mathilde CUENIN, MD · Contact
    • Mathilde CUENIN, MD · Principal investigator
  • Gustave Roussy
    Villejuif, 94800, France
    Recruiting
    • Angela BOTTICELLA, MD · Contact
    • Angela BOTTICELLA, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Sponsor will share de-identified data sets . Documents generated under the project will be disseminated in accordance with Institut Curie policies.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.

Access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Dec 2031, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2021
First posted
Feb 1, 2021
StartActual
Dec 28, 2021
Primary completionEst.
Dec 28, 2031
CompletionEst.
Dec 28, 2032
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04731610
Lead sponsor
Institut Curie
Responsible party
Sponsor
First posted
Feb 1, 2021
Start date
Dec 28, 2021
Primary completion
Dec 28, 2031 (estimated)
Completion
Dec 28, 2032 (estimated)
Last update
Apr 20, 2026

Study contacts

Nicolas GIRARD, PR
Contact
nicolas.girard2@curie.fr
(0)1 44 32 46 06 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion